[HTML] thelancet.com

[HTML][HTML] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 …

SM Lee, I Khan, S Upadhyay, C Lewanski… - The lancet …, 2012 - thelancet.com
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …
被引用次数：215 相关文章

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

SM Lee, I Khan, S Upadhyay, C Lewanski, S Falk… - Lancet Oncol, 2012 - thelancet.com
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

SM Lee, I Khan, S Upadhyay, C Lewanski, S Falk… - The Lancet …, 2012 - infona.pl
Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active
supportive care because of poor performance status or presence of several comorbidities …

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

SM Lee, I Khan, S Upadhyay… - The Lancet …, 2012 - pubmed.ncbi.nlm.nih.gov
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …
[PDF] core.ac.uk

[PDF][PDF] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 …

SM Lee, I Khan, S Upadhyay, C Lewanski, S Falk… - Lancet Oncol, 2012 - core.ac.uk
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

SM Lee, I Khan, S Upadhyay… - The Lancet …, 2012 - research.birmingham.ac.uk
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for
chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial — University of …
[PDF] researchgate.net

[PDF][PDF] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 …

SM Lee, I Khan, S Upadhyay, C Lewanski, S Falk… - Lancet …, 2012 - researchgate.net
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …

[引用][C] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 …

SM Lee, I Khan, S Upadhyay… - LANCET …, 2012 - openresearch.surrey.ac.uk
[HTML] sciencedirect.com

[HTML][HTML] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 …

SM Lee, I Khan, S Upadhyay, C Lewanski, S Falk… - The Lancet …, 2012 - Elsevier
BACKGROUND: Many patients with advanced non-small-cell lung cancer (NSCLC) receive
only active supportive care because of poor performance status or presence of several …
[HTML] nih.gov

[HTML][HTML] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 …

SM Lee, I Khan, S Upadhyay, C Lewanski… - The Lancet …, 2012 - ncbi.nlm.nih.gov
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …